We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Ethanol extract of Gleditsia sinensis thorn suppresses angiogenesis in vitro and in vivo
BMC Complementary and Alternative Medicinevolume 12, Article number: 243 (2012)
Gleditsia sinensis thorns have been widely used in traditional Korean medicine for the treatment of several diseases, including obesity, thrombosis, and tumor-related diseases. The aim of the study is to determine the antiangiogenic effect of Gleditsia sinensis thorns in vitro and in vivo in a bid to evaluate its potential as an anticancer drug.
Ethanol extract of Gleditsia sinensis thorns (EEGS) were prepared and used for in vitro and in vivo assays. In vitro antiangiogenic effect of EEGS was determined in HUVEC primary cells by cell migration and tube formation assays. In vivo antiangiogenic effect of EEGS was determined by measuring vessel formation and vascular endothelial cells migrating into the implanted matrigels in nude mice. The angiogenesis-related proteins of which expression levels were altered by EEGS were identified by proteomic analysis.
EEGS exerted a dose-dependent antiproliferative effect on HUVEC cells without significant cytotoxicity. Angiogenic properties, such as cell migration and tube formation, were significantly inhibited by EEGS in a dose-dependent manner. New vessel formation was also suppressed by EEGS, as determined by the directed in vivo angiogenesis assays in nude mice. EEGS reduced the expression of proangiogenic proteins, endothelin 1 and matrix metallopeptidase 2, in HUVEC cells.
Our findings suggest that EEGS can inhibit angiogenesis by down-regulating proangiogenic proteins, and therefore it should be considered as a potential anticancer drug targeting tumor-derived angiogenesis.
Angiogenesis is the physiological process of forming new blood vessels from the preexisting vasculature, and it is a vital process during embryonic development. However, in adults angiogenesis is only observed in specific areas, such as the endometrium and ovarian follicle cells . Angiogenesis also plays a key role in many diseases, including cancer, where it promotes tumor growth and metastasis . A continuous supply of nutrients and oxygen is critical for tumor growth; however, these factors are severely limited in the interior of solid tumors, and the tumor core undergoes apoptotic death in the absence of new blood vessels. Moreover, suitable tumor vasculature is also important for removing the metabolic waste produced by tumors, to maintain normal metabolic processes and for tumor development . In fact, the volume of a tumor cannot exceed >1 mm3 in an avascular state . Therefore, the inhibition of angiogenesis is a promising strategy for anticancer drug development.
Since 1971, when Folkman hypothesized that tumor growth is dependent on angiogenesis , considerable efforts have been dedicated to develop cancer therapies that target angiogenesis. Because angiogenesis is a multi-step and multi-factorial process, each step or factor could be a target of antiangiogenic cancer therapy. Current antiangiogenic therapies include natural angiogenesis inhibitors (e.g., angiostatin), endothelial cell growth inhibitors (e.g., TNP-470), inhibitors of proangiogenic molecules (e.g., vascular endothelial growth factor [VEGF] receptor antibodies), and therapies that interfere with basement membranes and the extracellular matrix (e.g., tissue inhibitors of matrix metallopeptidases [TIMPs]) . Endothelial cells have low mutagenesis rates and are unable to acquire multidrug resistance to cancer therapeutics, making angiogenesis an attractive anticancer target . An additional advantage is the ability of antiangiogenic drugs to target newly forming vessels without harming surrounding normal cells; therefore, they show lower toxicities than traditional cytotoxic chemotherapeutics. Thus cancer patients may be able to receive repeated cycles of therapy without serious side effects . In addition, antiangiogenic cancer drugs have the potential to treat a wide range of solid tumors because most tumors require neovasculature for propagation and metastasis. Previous studies have demonstrated that cancer cells release proangiogenic proteins, such as VEGF  and basic fibroblast growth factor (FGF2) . These growth factors recruit endothelial cells and promote their proliferation. Therefore, small molecules that interfere with the proangiogenic signaling pathway are potential anticancer drugs.
Traditional oriental medicine has used various parts of Gleditsia sinensis such as thorns, fruits, and anomalous fruits (fruits without seeds) to treat diverse diseases including thrombosis, obesity, and tumor-related disease [8–10]. In oncologic aspect the extract of Gleditsia sinensis thorn could prevent colon cancer in vitro and vivo through the induction of G2/M cell cycle arrest and extracellular signal-regulated kinase 1/2 (ERK1/2) activation , and cervical cancer in vivo through down-regulation of proliferating cell nuclear antigen (PCNA) and mutant p53 . The extract of anomalous fruits of Gleditsia sinensis induced apoptotic cell death in primary leukemic cells of cancer patients . In addition the extract of Gleditsia sinensis fruits showed anticancer effects in esophageal squamous cell carcinoma cell lines by inhibiting cyclooxygenase 2 (COX2) expression and telomerase activity . The extract of Gleditsia sinensis thorn was also known to have antiatherogenic effect in vascular smooth muscle cells by inhibiting cell proliferation and TNFα-induced matrix metallopeptidase 9 (MMP9) expression . However, the effect of EEGS on angiogenesis and its underlying mechanism are still in question in primary endothelial cells that form blood vessels. In this study, we demonstrated that the EEGS has antiangiogenic potential both in vitro and in vivo.
The thorn of Gleditsia sinensis L. (family Leguminosae) has been widely used in traditional Chinese and Korean medicine for the treatment of several diseases, including obesity, thrombosis, and tumor-related diseases [9, 10]. Lee et al. demonstrated that ethanol extract of the Gleditsia sinensis thorn (EEGS) showed antiproliferative potential in colon cancer cell lines in vitro and in vivo by inducing cancer cell growth arrest in the G2/M phase . However, the effect of EEGS on angiogenesis and its underlying mechanism are unknown in primary endothelial cells forming blood vessels. In this study, we demonstrated that the EEGS has antiangiogenic potential both in vitro and in vivo.
Preparation of EEGS
Gleditsia sinensis thorns were purchased from Kwangmyungdang Medicinal Herbs (Ulsan, Republic of Korea) in July 2010. Identity of the Gleditsia sinensis thorns was confirmed by Dr. Go Ya Choi, Basic Herbal Medicine Research Group, Herbal Medicine Research Division, Korea Institute of Oriental Medicine (KIOM). A voucher specimen (KIOM-CRC-1) was deposited at KM-Based Herbal Drug Research Group, Herbal Medicine Research Division, KIOM, Republic of Korea. Dried Gleditsia sinensis thorns (200 g) were finely pulverized and immersed in 70% (v/v) ethanol (100 g/L). The solvent extraction was performed by subjecting the mixtures to two consecutive 1 h periods of ultrasonication. The extracts were filtered through Whatman No.2 filter paper and concentrated in a rotary evaporator. The powdered extract (11.03 g) was homogenized using a mortar and stored at 4°C. The yield of the final extract was approximately 5.52% (w/w).
Human umbilical vein endothelial cells (HUVEC) were obtained from Lonza (Walkersvill, MD, U.S.A.). They were maintained in EGM-2 endothelial growth medium (Lonza) containing 2% fetal bovine serum (FBS), 0.4% FGF2, 0.1% VEGF, 0.1% R3-insulin-like growth factor 1 (R3-IGF1), 0.1% epidermal growth factor (EGF), 0.04% hydrocortisone, 0.1% ascorbic acid, 0.1% heparin, and 0.1% GA-1000 at 37°C in a humidified atmosphere containing 5% CO2. The culture medium was replaced with fresh medium every other day, and the cells were used for experiments between passage number 5 and 10.
Because the crude ethanol extracts were insoluble in water, EEGS was dissolved in dimethyl sulfoxide (DMSO, Sigma, St Louis, MO, U.S.A.) at a concentration of 20 mg/mL and stored at −70°C until use. One day before drug treatment, 5 × 103 cells were seeded into each well of a 24-well tissue culture plate that contained 450 μL of EGM-2. The cells were then treated with 50 μL of serially diluted test drugs and maintained for various periods. The higher maximum concentration of vehicle (1%) than usual (0.1-0.5%) was used in this study due to low solubility of EEGS. However, we found that neither cell viability nor in vitro angiogenesis of HUVEC cells was significantly affected by DMSO up to 1%. Drug-treated HUVEC cells were trypsinized and resuspended in cultured medium. The numbers of total (viable and dead) and dead cells were determined using an ADAM-MC automatic cell counter (NanoEnTek, Seoul, Republic of Korea). In brief, AccuStain T solution is a cell lysis solution supplemented with a DNA staining fluorescent dye (propidium iodide, PI), and AccuStain N solution is a saline solution containing only PI. The numbers of total (viable and dead) and dead cells were counted by mixing an equal volume of cell suspension with AccuStain T and AccuStain N, respectively, and by loading 20 μL of mixed solution into the T and N channels of AccuChip. The number of total cells and the cell viability were automatically calculated by ADAM-MC software.
Wound healing assay
HUVEC cells, cultured in 24-well plates, were scratched with a yellow tip at 90% confluence and photographs were taken using an inverted microscope (Olympus IX71, Tokyo, Japan). Cells were washed with fresh EGM-2 and further incubated in fresh EGM-2 with various concentrations of EEGS. After 12 h, photographs were taken and wound healing was digitally quantified using MetaMorph image analysis software (Molecular Devices, Downingtown, PA, U.S.A.). The healing area (%) was calculated according to the following formula: healing area (%) = [1-wounded area (t=12 h)/wounded area (t = 0 h)] × 100.
Tube formation assay
The antiangiogenic potential of EEGS was tested using a Cultrex in vitro angiogenesis assay kit (Trevigen, Gaithersburg, MD, U.S.A.) according to the manufacturer’s instructions. One hundred microliters of HUVEC cells (1.5 × 105 cells/mL) were resuspended in EGM-2 with various concentrations of EEGS and added to a 96–well plate that was precoated with basement membrane extracts (BME). After 12 h cultivation at 37°C, tubes were photographed using a microscope. Sulforaphane (5 μM) was included in the tube formation assay as a positive control . The tube length and branch points were digitally quantified using MetaMorph image analysis software.
In vivo angiogenesis assay
In vivo angiogenesis was assayed using the directed in vivo angiogenesis assay (DIVAA) kit (Trevigen) according to the manufacturer’s instructions. In brief, angioreactors, silicone cylinders closed at one end, were filled with growth factor-reduced BME premixed with combination of angiogenic factors (VEGF, FGF2) and different concentrations of EEGS (0, 50, 100 and 200 μg/ml). Angioreactors were inverted and incubated at 37°C for 1 h to allow gel formation before subcutaneous implantation into the dorsal flanks of the 6-week-old nude mice. After 12 days, the angioreactors were harvested and vessel formation was photographed. Vascular endothelial cells migrating into the BME to form vessels in the angioreactor were quantified by FITC-lectin detection. The fluorescence intensity was measured at a wavelength of excitation 485 nm and emission 510 nm with a fluorescence microplate reader (SPECTRA MAX GEMINI EM, Molecular Devices). The fluorescence intensity is proportional to the number of endothelial cells migrating into the BME gels of implanted cylinder. The relative angiogenesis were normalized to the mean of the positive control. All experiments involving mice were approved by the Institutional Animal Care and Use Committee at the Korea Institute of Oriental Medicine (Protocol # 12–058).
HUVEC cells were cultured in 100-mm tissue culture dishes containing EGM-2 media until they reached 75-80% confluence. The cells were washed with PBS and incubated in EGM-2 media with or without EEGS for the indicated times. The cultured medium was collected and centrifuged for further analysis. The cells were rinsed with ice cold PBS and solubilized in lysis buffer (1% NP-40, 20 mM Tris–HCl, pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM EDTA, 10 μg/mL aprotinin, 10 μg/mL pepstatin and 10 μg/mL leupeptin) by gentle rocking at 4°C for 30 min. The insoluble debris was removed by centrifugation at 14,000 × g for 5 min at 4°C, and the soluble fractions were collected. Protein concentrations were determined using the BCA protein assay kit (Pierce, Rockford, IL, U.S.A.), and 200 μg of cell lysate or 100 μL of culture supernatant were incubated with human angiogenesis array membranes (Proteome Profiler™, R&D Systems). The proteome profiles were developed according to the manufacturer’s instructions. Membrane-bounds proteins were visualized using Supersignal west femto chemiluminescent substrates (Pierce), and the images were captured on a Fusion SL4 imaging system (Fisher Biotec, Wembley, Australia).
The amount of endothelin 1 (EDN1) released from HUVEC cells was quantified using the human EDN1 immunoassay kit (R&D Systems, Minneapolis, MN, U.S.A.) according to the manufacturer's instructions. In brief, cultured medium was centrifuged to remove particulates and the supernatants were aliquoted and stored at −20°C. The recombinant EDN1 standards and samples were loaded into separate wells of a microplate that was precoated with an EDN1 monoclonal antibody, and the samples were incubated for 1 h at room temperature (RT). After washing, EDN1 conjugates were added to each well and incubated for 3 h at RT. After washing, a substrate solution was added and incubated for 30 min. Color development was monitored using a microplate reader (Emax, Molecular Devices) at 450 nm, and the concentration of EDN1 was calculated from the standard curve.
Activity gel for matrix metallopeptidase 2
The activity of matrix metallopeptidase 2 (MMP2) was determined using a gelatin zymogram as previously described . In brief, cultured medium was centrifuged at 1,000 rpm for 5 min at 4°C to remove cellular debris. The supernatants were then concentrated using a Vivaspin 6 (GE healthcare, Piscataway, NJ, U.S.A.) with a molecular weight cutoff size of 5 kDa. The protein concentration of the medium was quantified using a 2D quant kit (GE healthcare), and 30 μg of protein was mixed with SDS-PAGE loading buffer without reducing agent. The protein samples were incubated at 24°C for 30 min and separated on a 7.5% SDS-PAGE gel copolymerized with 1 mg/mL gelatin (Sigma). The gels were washed three times (30 min at 24°C) with 2.5% (v/v) Triton X-100 to remove SDS, and then incubated in a buffer composed of 50 mM Tris (pH 7.6), 1 μM ZnCl2, and 5 mM CaCl2 for 18 h at 37°C. The gels were stained with 0.1% Coomassie blue solution.
Real-time polymerase chain reaction (RT-PCR)
TaqMan RT-PCR was performed to determine the effect of the EEGS on intracellular mRNA levels of EDN1 and MMP2. Total RNA was prepared from HUVEC cells that had been cultured in the presence or absence of EEGS using the Easy-spin™ total RNA extraction kit (iNtRON biotechnology, Seoul, Republic of Korea). The integrity of the isolated total RNA was confirmed by agarose gel electrophoresis. Single-stranded cDNA was synthesized from 5 μg of total RNA using the SuperScript™ III first strand synthesis system (Invitrogen, Carlsbad, CA, U.S.A.). Pre-validated probe and primer sets for EDN1 (ABI ID, Hs00174961_m1; FAM-labeled), MMP2 (ABI ID, Hs01548727_m1; FAM-labeled), and β-actin (ABI ID, Hs99999903_m1; VIC-labeled) were purchased from Applied Biosystems (Foster City, CA, U.S.A.). The PCR reaction and determination of the relative expression of specific genes were carried out in the Applied Biosystems Sequence Detection System 7500.
The differences in continuous variables were determined by a one-way analysis of variance (ANOVA) and Tukey’s HSD post-hoc test. Statistical significance was set at p<0.05.
EEGS inhibits cell proliferation but does not induce cell death in HUVEC cells
Proliferation of endothelial cells in response to angiogenic stimuli is a critical step during new vessel formation . To determine the effect of EEGS on HUVEC cell growth, HUVEC cells were cultured in EGM-2 media containing endothelial growth factors and exposed to increasing concentrations of EEGS (0–200 μg/mL). At regular time intervals, total (viable and dead) cell numbers and viability were calculated using an automatic cell counter that assessed the cytoplasmic membrane integrity as described in the Methods. As shown in Figure 1A, EEGS treatment inhibited cell proliferation in a dose-dependent manner. A significant inhibitory effect on cell proliferation was observed in response to EEGS at ≥50 μg/mL concentrations. The highest dose (200 μg/mL) of EEGS inhibited cellular proliferation completely throughout the 48 h cultivation period. However, the antiproliferative effect of EEGS was not related to cytotoxicity (Figure 1B). Although a slight decrease in cell viability was observed in the EEGS-treated HUVEC cells, no significant cytotoxicity was observed at doses of up to 200 μg/mL EEGS during the 48 h cultivation period. The antiproliferative potential of EEGS was also observed under the microscope (Figure 1C). Although increasing concentrations of EEGS induced morphological changes and growth arrest, significant cell death was not observed during 48 h of treatment.
EEGS inhibits angiogenic properties in HUVEC cells in vitro
Angiogenesis mediated by vascular endothelial cells is characterized by cell migration to designated sites of new blood vessel formation. Thus, the antiangiogenic potential of EEGS in HUVEC cells was determined using an in vitro wound healing assay. In the absence of EEGS treatment, HUVEC cells found at the border of scratches (Figure 2A, left panel, T = 0) migrated rapidly toward the wounded area and covered it within 12 h (0 μg/mL of EEGS). However, cell mobility was slowed by EEGS treatment in a dose-dependent manner, and HUVEC cells treated with 200 μg/mL of EEGS showed no movement. A significant decrease in cell mobility was observed at a concentration of ≥50 μg/mL, and only 10% of the wound was covered at an EEGS concentration of 200 μg/mL (Figure 2A, right panel). In addition, we evaluated the effect of EEGS treatment on tube formation by HUVEC cells. On a matrix-coated surface, HUVEC cells are capable of building tubes via connecting to neighboring cells in the presence of growth factors (Figure 2B, left panel, 0 μg/mL of EEGS). However, in the presence of EEGS, the intercellular connection was limited and HUVEC cells failed to form tubes. To quantify the degree of tube formation, photographs were taken at the end of each experiment under the microscope, and tube length and branch numbers were calculated using image analysis software (Figure 2B, right panel). Both parameters decreased in a dose-dependent manner following EEGS treatment. Statistical analyses revealed that both tube length and branch number were significantly reduced at ≥100 μg/mL concentrations of EEGS. The inhibitory effect of 100 μg/mL of EEGS on HUVEC cell tube formation was comparable to that of 5 μM sulforaphane, a positive control for tube formation inhibition.
EEGS inhibits angiogenesis in vivo
Because EEGS inhibited in vitro angiogenic properties, such as cell migration and tube formation, we next investigated its effect on angiogenesis in vivo using commercially available direct in vivo angiogenesis kit as described in Methods. As shown in Figure 3 (top panel), massive vessel ingrowth from the open ends of angioreactors was observed in the presence of VEGF/FGF2 angiogenic factors but in the absence of EEGS (positive control). However, EEGS treatment suppressed the vessel ingrowth induced by angiogenic factors in a dose-dependent manner as determined by FITC-lectin labeling of endothelial cells to form new vessels (bottom panel). Antiangiogenic effect of EEGS was observed at ≥50 μg/mL concentration and complete inhibition of vessel formation was observed at 200 μg/mL of EEGS. New vessel formation was limited in the absence of both VEGF/FGF2 and EEGS (negative control).
EEGS down-regulates the expression of proangiogenic proteins
To identify proteins of which expression levels are altered in response to EEGS treatment, a proteomic analysis was carried out using cultured media or cell lysates prepared from HUVEC cells that had been treated with 100 μg/mL EEGS or vehicle for 8 h. Membranes arrayed with specific antibodies for angiogenesis-related proteins were incubated with cultured medium or cell lysates, and the protein expression profiles were compared by analyzing dot intensities (Figure 4A). We observed significant changes in the protein expression of FGF2 and EDN1. Treatment of 100 μg/mL EEGS decreased the EDN1 expression by 34.8% (p<0.001) in the cultured media, and by 55.2% (p<0.001) in the cell lysate compared with the negative vehicle control. Because the expression of FGF2, which was supplemented in EGM-2 endothelial growth medium, was decreased by EEGS only in cultured media (41.7%, p<0.01) but not in the cell lysate (122.5%, p=0.210), it was excluded from our further studies. It is possible that HUVEC cells treated with EEGS may consume FGF2 more rapidly than HUVEC cells treated with DMSO by an unknown mechanism. The proangiogenic protein, EDN1, showed the most dramatic and reproducible change in protein levels in both cell lysate and cultured media. To verify the EEGS-induced EDN1 down-regulation observed in the proteomic analysis, we performed an EDN1 immunoassay using a commercially available kit (Figure 4B, left panel). Without EEGS treatment, extracellular EDN1 increased continuously throughout the culture period. However, in the presence of EEGS, the rate of EDN1 production decreased in a dose-dependent manner. Treatment with 200 μg/mL EEGS almost completely inhibited EDN1 production after 4 h. Next, we determined the effect of EEGS treatment on the level of intracellular EDN1 mRNA using RT-PCR. Total RNA and cDNA were prepared from HUVEC cells that were treated with increasing concentrations (0–200 μg/mL) of EEGS for 8 h. EEGS treatment reduced the level of intracellular EDN1 mRNA in a dose-dependent manner (Figure 4B, right panel), and 200 μg/mL of EEGS decreased EDN1 mRNA levels by more than 90%. These data suggest that EEGS down-regulates EDN1 mRNA levels, leading to reduced EDN1 production.
MMP2 and MMP9 are key enzymes involved in angiogenesis during cancer development. Proteomic analysis revealed no change in MMP9 expression following EEGS treatment. However, MMP2 was not arrayed on the proteome membrane chip, and therefore we investigated the effect of EEGS on the activity of MMP2 in HUVEC cell cultured media using zymogram. MMP2 can hydrolyze a gelatin substrate incorporated into an SDS-PAGE gel, and gelatin hydrolysis by MMP2 can be visualized by Coomassie staining. The activity of MMP2 in the zymogram was decreased by EEGS in a dose-dependent manner (Figure 4C, left panel). Western blot analysis revealed that reduced MMP2 activity correlated with a decrease in the level of MMP2 protein secreted into the cultured medium. To further understand the EEGS-induced reduction in MMP2 activity, the intracellular mRNA levels of MMP2 were investigated using RT-PCR. Total RNA and cDNA were prepared from HUVEC cells that were treated with increasing concentrations (0–200 μg/mL) of EEGS for 8 h. Intracellular mRNA levels of MMP2 were reduced in a dose-dependent manner (Figure 4C, right panel), which may explain the decrease in MMP2 activity in cultured media, as shown in the zymogram.
Although massive tumors can be treated by surgical intervention, treatment of small primary tumors or cancers undergoing metastasis largely relies on chemotherapy . However, the clinical use of cytotoxic cancer drugs, which target uncontrolled, dividing cancer cells, is limited by the severe side effects caused by killing fast dividing normal cells, such as blood cells. Therefore, many cytotoxic cancer drugs currently in development are designed to attack only cancer cells. This targeted therapy is achieved by conjugating cytotoxic drugs with monoclonal antibodies that recognize cancer specific molecules. However, a disadvantage of these “magic bullet” cancer drugs is that they demonstrate variable efficacy depending on the cancer type and the genetic background of the patient [18, 19]. Another limitation of cytotoxic anticancer drugs is that these chemicals can induce drug resistance in cancer cells as a result of tumor drug efflux . Therefore, the drug dose may need to be increased to induce the same therapeutic response over time.
New blood vessel formation, or angiogenesis, is important for many physiological processes throughout the entire human lifespan, including fetal development. It is also critical for tumor development, as first suggested almost 40 years ago by Folkman [5, 21]. Anticancer drugs developed to inhibit angiogenesis have been demonstrated to inhibit tumor growth by targeting molecules within the angiogenic signaling pathway. Bevacizumab (trade name, AVASTIN®, Genentech/Roche), a monoclonal antibody raised against human vascular endothelial growth factor A (VEGFA) inhibits the VEGFA signaling pathway, which is involved in tumor-derived angiogenesis . It was the first FDA-approved drug for the treatment of metastatic colon cancer and advanced non-small cell lung cancer [23, 24]. Because of their relatively low cytotoxicity, antiangiogenic drugs may be used repeatedly and for long-term cancer therapy. Tumor-driven angiogenesis is a nearly universal characteristic of cancer, suggesting that antiangiogenic drugs may have a wide range of clinical applications for cancer therapy . Three major strategies that have been explored so far are as follows: 1) blockade of pro-angiogenic growth factors and their specific signaling pathways, 2) enhancement of the levels of antiangiogenic factors, and 3) disruption of abnormal cancerous vascular function . The aim of this study was to validate EEGS as a potential antiangiogenic agent because the source of EEGS, the Gleditsia sinensis thorn, is a herbal drug that has been commonly prescribed for thrombosis and tumor-related diseases in the traditional Korean medicine. The antiangiogenic potential of EEGS was explored using well established in vitro/in vivo angiogenesis assays.
Angiogenesis is a multi-step process requiring coordinated endothelial functions, such as cell migration, proliferation and extracellular matrix remodeling . In this study, we employed HUVEC cells for in vitro assays representing several angiogenic functions because they are a well-known macrovasculature model and are susceptible to antiangiogenic drugs . Our in vitro assays demonstrated that EEGS inhibited HUVEC cell proliferation (Figure 1A) and cellular mobility (Figure 2A). These cellular processes are related to the angiogenic properties of HUVEC cells, and inhibition of these angiogenic properties by EEGS resulted in global inhibition of HUVEC cell tube formation on matrigel at EEGS concentrations of ≥50 μg/mL for tube branching and ≥100 μg/mL for both tube branching and length (Figure 2B). EEGS-mediated inhibition of the angiogenic functions of HUVEC cells was replicated in the direct in vivo angiogeneis assays using nude mice (Figure 3).
Cell growth, which is determined by the balance between cell amplification and death, affects angiogenesis. To rule out the effect of EEGS-induced cytotoxicity on angiogenesis, we investigated the cytotoxicity of EEGS in HUVEC cells in the presence of increasing concentrations of drug, up to 200 μg/mL. Although EEGS induced dramatic antiproliferative effects at a concentration of ≥50 μg/mL (Figure 1A), cell viabilities was not significantly changed at doses as high as 200 μg/mL, as determined by membrane integrity or morphological observation (Figure 1B and C). These results indicate that the antiangiogenic potential of EEGS is not due to cytotoxicity. Therefore, we can separate the antiangiogenic effects of EEGS from its cytotoxic effect within the range of concentrations used in this study (0–200 μg/mL). Paclitaxel, a microtubule-damaging anticancer agent, exerts similar in vitro effects on endothelial cells. At high concentrations, paclitaxel exerts cytotoxic effects by inducing mitochondria-mediated apoptosis; however, at low concentrations, it induces cytostatic effects by slowing down the cell cycle, which is associated with antiangiogenic activity in endothelial cells . The inhibitory effect of EEGS on angiogenic functions in HUVEC cells appeared to be reversible because removal of EEGS was sufficient to release cells from EEGS-induced cell migration arrest (data not shown). Recently, Lu et al. (2012)  reported that six active components of saponin fraction from Gleditsia sinensis fruits (gleditsiosides B, I, J, O, Q, and B) exerted in vitro antiangiogenic effects on HUVEC cells. However, they also showed that the active saponin compounds induced significant apoptotic cell death in HUVEC cells by enhancing caspase 3/8 expression, which were quite different results from ours. Therefore, our data suggest that the antiangiogenic potential of EEGS may come from active constituent(s) other than saponin compounds.
Proteomic and immunoassay studies showed that both intracellular and extracellular levels of EDN1 were decreased by EEGS treatment in a dose-dependent manner (Figure 4A and B). Furthermore, intracellular EDN1 mRNA levels correlated with changes in extracellular EDN1 levels. EDN1 is one of three 21-amino acid peptide family members (EDN1, EDN2, and EDN3) , and it is known to be a proangiogenic modulator that promotes endothelial cell proliferation and migration through two G protein coupled receptors (ETAR and ETBR) . EDN1 is also known to have effects on the growth and progression of various tumor types by affecting proliferation and resistance to apoptosis . In our study, EEGS treatment reduced the extracellular and intracellular levels of EDN1, suggesting that reducing EDN1 is one of the mechanisms by which EEGS inhibits the angiogenic functions of HUVEC cells.
Because some effective antitumor agents targeting tumor vessel formation have been shown to reduce MMP2 activity [29, 30] and MMP2 produced by endothelial cells is known to contribute to the progress of angiogenesis , we investigated MMP2 enzyme activity in response to EEGS treatment. The activity of extracellular MMP2 was decreased by EEGS treatment in a dose-dependent manner (Figure 4C). Each regulatory step, such as transcription, translation, translational modification or extracellular secretion of expressed proteins can affect MMP2 activity in cultured media. In the present study, we observed that the decrease in MMP2 activity in HUVEC cell cultured media correlated with decreased levels of extracellular MMP2 proteins (Figure 4C, left panel) and intracellular MMP2 mRNA (Figure 4C, right panel). Therefore, EEGS down-regulates MMP2 mRNA expression, leading to reduced MMP2 protein. However, we did not investigate the mechanism by which EEGS treatment down-regulates MMP2 mRNA expression in the present study. It is possible that EEGS inhibits the transcription of MMP2 or affects the stability of MMP2 mRNA in HUVEC cells. Taken together, our data suggest that EEGS exerts its antiangiogenic effects on HUVEC primary endothelial cells by inhibiting the expression and/or activity of proangiogenic proteins.
Most previous phytochemical studies on Gleditsia sinensis were carried out using its fruit and anomalous fruit parts. The single compounds from the fruits or anomalous fruits of Gleditsia sinensis have been isolated as triterpene (echinocystic acid), flavonoid (aromadendrin), polyphenol (ellagic acid glycosides), and triterpenoid saponins (gleditsioside A-K, N-Q, and Z) [31–40]. Their identified pharmacological activities were antagonistic against dopamine D1 receptor (gleditsioside F) , protective against acute myocardial ischemia (echinocystic acid)  or type 2 diabetes mellitus (aromadendrin) , antiallergic in mast cells (saponins) , and cytotoxic to leukemic cells (gleditsioside E) . The single compounds from the Gleditsia sinensis thorns were isolated as a lupane acid with anti-HIV activity , and triterpenoid (D:C-friedous-7-en-3-one) and sterols with antimutagenic activity . To our knowledge, there was no study reporting antiangiogenic active compound(s) from the Gleditsia sinensis. We are trying to identify antiangiogenic active single compound(s) from the extract of Gleditsia sinensis thorn using in vitro activity-guided fractionation.
Because tumor angiogenesis is a very complex progress involving diverse cell types, agents with multi-targets or a combination of targeted single agents are needed to target angiogenesis as an anticancer strategy. In vitro and in vivo assays clearly identified EEGS as an antiangiogenic herbal drug. Thus, EEGS is a promising antiangiogenic cancer drug that warrants further development. The inhibitory effects of EEGS are likely due to down-regulation of intra/extracellular proangiogenic modulators, such as EDN1 and MMP2 enzymes. At present, the mechanisms by which EEGS suppresses the expression of proangiogenic modulators were not fully characterized in this study. Further studies are needed to identify the molecule(s) responsible for EEGS-mediated antiangiogenesis.
Matsunaga N, Chikaraishi Y, Shimazawa M, Yokota S, Hara H: Vaccinium myrtillus (bilberry) extracts reduce angiogenesis In vitro and In vivo. Evid Based Complement Alternat Med. 2010, 7: 47-56. 10.1093/ecam/nem151.
Tandle A, Blazer DG, Libutti SK: Antiangiogenic gene therapy of cancer: recent developments. J Transl Med. 2004, 2: 22-10.1186/1479-5876-2-22.
Papetti M, Herman IM: Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol. 2002, 282: C947-C970.
Tosetti F, Ferrari N, De Flora S, Albini A: Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 2002, 16: 2-14. 10.1096/fj.01-0300rev.
Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971, 285: 1182-1186. 10.1056/NEJM197111182852108.
Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997, 390: 404-407. 10.1038/37126.
Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med. 2003, 9: 669-676. 10.1038/nm0603-669.
Dai Y, Chan YP, Chu LM, Bu PP: Antiallergic and anti-inflammatory properties of the ethanolic extract from gleditsia sinensis. Biol Pharm Bull. 2002, 25: 1179-1182. 10.1248/bpb.25.1179.
Lai P, Du JR, Zhang MX, Kuang X, Li YJ, Chen YS, He Y: Aqueous extract of gleditsia sinensis Lam. Fruits improves serum and liver lipid profiles and attenuates atherosclerosis in rabbits fed a high-fat diet. J Ethnopharmacol. 2011, 137: 1061-1066. 10.1016/j.jep.2011.06.023.
Lee SJ, Park K, Ha SD, Kim WJ, Moon SK: Gleditsia sinensis thorn extract inhibits human colon cancer cells: the role of ERK1/2, G2/M-phase cell cycle arrest and p53 expression. Phytother Res. 2010, 24: 1870-1876. 10.1002/ptr.3214.
Long L, Geng GX, Li QW: Effect of gleditsia sinensis stings on growth inhibition and expression of PCNA and p53 in mice bearing uterine cervical carcinoma (U14). Zhongguo Zhong Yao Za Zhi. 2006, 31: 150-153.
Chui CH, Lau FY, Chan AS, Cheng GY, Wong RS, Lai KB, Kok SH, Yeung TT, Teo IT, Yau MY: Gleditsia sinensis fruit extract-induced apoptosis involves changes of reactive oxygen species level, mitochondrial membrane depolarization and caspase 3 activation. Int J Mol Med. 2005, 15: 539-543.
Pak KC, Lam KY, Law S, Tang JC: The inhibitory effect of gleditsia sinensis on cyclooxygenase-2 expression in human esophageal squamous cell carcinoma. Int J Mol Med. 2009, 23: 121-129.
Lee SJ, Park SS, Kim WJ, Moon SK: Gleditsia sinensis thorn extract inhibits proliferation and TNF-alpha-induced MMP-9 expression in vascular smooth muscle cells. Am J Chin Med. 2012, 40: 373-386. 10.1142/S0192415X12500292.
Asakage M, Tsuno NH, Kitayama J, Tsuchiya T, Yoneyama S, Yamada J, Okaji Y, Kaisaki S, Osada T, Takahashi K: Sulforaphane induces inhibition of human umbilical vein endothelial cells proliferation by apoptosis. Angiogenesis. 2006, 9: 83-91. 10.1007/s10456-006-9034-0.
Salani D, Taraboletti G, Rosano L, Di Castro V, Borsotti P, Giavazzi R, Bagnato A: Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol. 2000, 157: 1703-1711. 10.1016/S0002-9440(10)64807-9.
Cardenas C, Quesada AR, Medina MA: Anti-angiogenic and anti-inflammatory properties of kahweol, a coffee diterpene. PLoS One. 2011, 6: e23407-10.1371/journal.pone.0023407.
Wong KK: Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. Lung Cancer. 2008, 60 (Suppl 2): 10-18.
Dimitrov DS, Marks JD: Therapeutic antibodies: current state and future trends–is a paradigm change coming soon?. Methods Mol Biol. 2009, 525: 1-27. 10.1007/978-1-59745-554-1_1.
Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 2010, 46: 308-316. 10.1007/s12033-010-9321-2.
Folkman J, Merler E, Abernathy C, Williams G: Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971, 133: 275-288. 10.1084/jem.133.2.275.
Lord S, Harris AL: Angiogenesis - still a worthwhile target for breast cancer therapy?. Breast Cancer Res. 2010, 12 (Suppl 4): 19-10.1186/bcr2748.
Planchard D: Bevacizumab in non-small-cell lung cancer: a review. Expert Rev Anticancer Ther. 2011, 11: 1163-1179. 10.1586/era.11.80.
Scott LJ: Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs. 2007, 67: 1793-1799. 10.2165/00003495-200767120-00009.
Kumaran G, Clamp AR, Jayson GC: Angiogenesis as a therapeutic target in cancer. Clin Med. 2008, 8: 455-458.
Pasquier E, Carre M, Pourroy B, Camoin L, Rebai O, Briand C, Braguer D: Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther. 2004, 3: 1301-1310.
Lu D, Xia Y, Tong B, Zhang C, Pan R, Xu H, Yang X, Dai Y: In vitro anti-angiogenesis effects and active constituents of the saponin fraction from gleditsia sinensis. Integr Cancer Ther. 2012, 10.1177/1534735412442377.
Bagnato A, Rosano L: The endothelin axis in cancer. Int J Biochem Cell Biol. 2008, 40 (8): 1443-1451. 10.1016/j.biocel.2008.01.022.
Miyake JA, Benadiba M, Colquhoun A: Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression. Lipids Health Dis. 2009, 8: 8-10.1186/1476-511X-8-8.
Lu MK, Chen PH, Shih YW, Chang YT, Huang ET, Liu CR, Chen PS: Alpha-chaconine inhibits angiogenesis in vitro by reducing matrix metalloproteinase-2. Biol Pharm Bull. 2010, 33: 622-630. 10.1248/bpb.33.622.
Zhang Z, Koike K, Jia Z, Nikaido T, Guo D, Zheng J: Four new triterpenoidal saponins acylated with one monoterpenic acid from gleditsia sinensis. J Nat Prod. 1999, 62: 740-745. 10.1021/np980441k.
Wu J, Li J, Zhu Z, Huang G, Tang Y, Gao X: Protective effects of echinocystic acid isolated from gleditsia sinensis Lam. Against acute myocardial ischemia. Fitoterapia. 2010, 81: 8-10. 10.1016/j.fitote.2009.06.015.
Yu S, Park JS, Paredes V, Song MC, Baek NI, Lee SI, Lim JS, Cho NY, Yoon J, Baek K: Screening and isolation of a natural dopamine D1 receptor antagonist using cell-based assays. J Biotechnol. 2010, 145: 304-309. 10.1016/j.jbiotec.2009.12.005.
Zhang Z, Koike K, Jia Z, Nikaido T, Guo D, Zheng J: Triterpenoidal saponins from gleditsia sinensis. Phytochemistry. 1999, 52: 715-722. 10.1016/S0031-9422(99)00238-1.
Zhang WY, Lee JJ, Kim IS, Kim Y, Myung CS: Stimulation of glucose uptake and improvement of insulin resistance by aromadendrin. Pharmacology. 2011, 88: 266-274. 10.1159/000331862.
Zhou L, Li D, Jiang W, Qin Z, Zhao S, Qiu M, Wu J: Two ellagic acid glycosides from gleditsia sinensis Lam. With antifungal activity on magnaporthe grisea. Nat Prod Res. 2007, 21: 303-309. 10.1080/14786410701192702.
Zhang Z, Koike K, Jia Z, Nikaido T, Guo D, Zheng J: Gleditsiosides N-Q, new triterpenoid saponins from gleditsia sinensis. J Nat Prod. 1999, 62: 877-881. 10.1021/np990060m.
Zhong L, Qu G, Li P, Han J, Guo D: Induction of apoptosis and G2/M cell cycle arrest by gleditsioside E from gleditsia sinensis in HL-60 cells. Planta Med. 2003, 69: 561-563.
Gao ZZ, Xia YF, Yao XJ, Dai Y, Wang Q: A new triterpenoid saponin from gleditisia sinensis and structure-activity relationships of inhibitory effects on lipopolysaccharide-induced nitric oxide production. Nat Prod Res. 2008, 22: 320-332. 10.1080/14786410701766422.
Zhang Z, Koike K, Jia Z, Nikaido T, Guo D, Zheng J: Triterpenoidal saponins acylated with two monoterpenic acids from gleditsia sinensis. Chem Pharm Bul. 1999, 47: 388-393. 10.1248/cpb.47.388.
Chong W, Feng XY, Zhen GZ, Dan L, Yue D: Inhibition of mast cell degranulation by saponins from gleditsia sinensis–structure-activity relationships. Nat Prod Commun. 2009, 4: 777-782.
Li WH, Zhang XM, Tian RR, Zheng YT, Zhao WM, Qiu MH: A new anti-HIV lupane acid from Gleditsia sinensis Lam. J Asian Nat Prod Res. 2007, 9: 551-555. 10.1080/10286020600883419.
Lim JC, Park JH, Budesinsky M, Kasal A, Han YH, Koo BS, Lee SI, Lee DU: Antimutagenic constituents from the thorns of gleditsia sinensis. Chem Pharm Bul. 2005, 53: 561-564. 10.1248/cpb.53.561.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/12/243/prepub
The authors sincerely thank Dr. Go Ya Choi, Dr. Sungwook Chae, and Hye Won Lee (Herbal Medicine Research Division, KIOM) for the identification of Gleditsia sinensis thorns and preparation of the herbal extract. This research was supported by a grant from the Korea Institute of Oriental Medicine (KIOM, K12061).
The authors have declared that there is no competing interest.
JMY and NSK carried out study concept, experimental design, data acquisition and analysis, and drafted the manuscript. JSP and SMO carried out data acquisition and analysis, and assisted with drafting manuscript. JL, JK, and DSO assisted with study concept, drafting, and revising the manuscript. OSB supervised the study and assisted with study concept and revising the manuscript. All authors read and approved the final manuscript for submission.